Literature DB >> 15530041

In vitro targeting of synthesized antibody-conjugated dendrimer nanoparticles.

Thommey P Thomas1, Anil K Patri, Andrzej Myc, Mon Thiri Myaing, Jing Yong Ye, Theodore B Norris, James R Baker.   

Abstract

This study reports the synthesis and in vitro biological properties of dendrimer-antibody conjugates. The polyamidoamine dendrimer platform was conjugated to fluorescein isothiocyanate as a means to analyze cell binding and internalization. Two different antibodies, 60bca and J591, which bind to CD14 and prostate-specific membrane antigen (PSMA), respectively, were used as model targeting molecules. The binding of the antibody-conjugated dendrimers to antigen-expressing cells was evaluated by flow cytometry, confocal microscopy, and a new two-photon-based optical fiber fluorescence detection system. The conjugates specifically bound to the antigen-expressing cells in a time- and dose-dependent fashion, with affinity similar to that of the free antibody. Confocal microscopic analysis suggested at least some cellular internalization of the dendrimer conjugate. Dendrimer-antibody conjugates are a suitable platform for targeted molecule delivery into antigen-expressing cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15530041     DOI: 10.1021/bm049704h

Source DB:  PubMed          Journal:  Biomacromolecules        ISSN: 1525-7797            Impact factor:   6.988


  26 in total

1.  Holistic assessment of covalently labeled core-shell polymeric nanoparticles with fluorescent contrast agents for theranostic applications.

Authors:  Tiffany P Gustafson; Young H Lim; Jeniree A Flores; Gyu Seong Heo; Fuwu Zhang; Shiyi Zhang; Sandani Samarajeewa; Jeffery E Raymond; Karen L Wooley
Journal:  Langmuir       Date:  2014-01-06       Impact factor: 3.882

2.  Nanoparticles: Emerging carriers for drug delivery.

Authors:  Sagar R Mudshinge; Amol B Deore; Sachin Patil; Chetan M Bhalgat
Journal:  Saudi Pharm J       Date:  2011-04-21       Impact factor: 4.330

Review 3.  Imaging applications of nanotechnology in cancer.

Authors:  U Ayanthi Gunasekera; Quentin A Pankhurst; Michael Douek
Journal:  Target Oncol       Date:  2009-10-30       Impact factor: 4.493

Review 4.  Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances.

Authors:  Nishant S Gandhi; Rakesh K Tekade; Mahavir B Chougule
Journal:  J Control Release       Date:  2014-09-07       Impact factor: 9.776

5.  Enzyme-responsive polymeric micelles of cabazitaxel for prostate cancer targeted therapy.

Authors:  Ashutosh Barve; Akshay Jain; Hao Liu; Zhen Zhao; Kun Cheng
Journal:  Acta Biomater       Date:  2020-06-18       Impact factor: 8.947

6.  In quest of a systematic framework for unifying and defining nanoscience.

Authors:  Donald A Tomalia
Journal:  J Nanopart Res       Date:  2009-05-26       Impact factor: 2.253

7.  A calcium-sensitive promoter construct for gene therapy.

Authors:  E Merlet; L Lipskaia; A Marchand; L Hadri; N Mougenot; F Atassi; L Liang; S N Hatem; R J Hajjar; A-M Lompré
Journal:  Gene Ther       Date:  2012-03-29       Impact factor: 5.250

8.  Dendrimer-based tumor cell targeting of fibroblast growth factor-1.

Authors:  Thommey P Thomas; Rameshwer Shukla; Alina Kotlyar; Jola Kukowska-Latallo; James R Baker
Journal:  Bioorg Med Chem Lett       Date:  2009-12-03       Impact factor: 2.823

Review 9.  Prostate cancer relevant antigens and enzymes for targeted drug delivery.

Authors:  Ashutosh Barve; Wei Jin; Kun Cheng
Journal:  J Control Release       Date:  2014-05-27       Impact factor: 9.776

Review 10.  Cancer active targeting by nanoparticles: a comprehensive review of literature.

Authors:  Remon Bazak; Mohamad Houri; Samar El Achy; Serag Kamel; Tamer Refaat
Journal:  J Cancer Res Clin Oncol       Date:  2014-07-09       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.